Illumina, Inc. (NASDAQ:ILMN) SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction on Monday, November 12th. The stock was sold at an average price of $314.63, for a total value of $3,146,300.00. Following the completion of the sale, the senior vice president now directly owns 79,612 shares of the company’s stock, valued at $25,048,323.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Mostafa Ronaghi also recently made the following trade(s):

  • On Wednesday, October 10th, Mostafa Ronaghi sold 10,000 shares of Illumina stock. The stock was sold at an average price of $311.84, for a total value of $3,118,400.00.
  • On Monday, September 10th, Mostafa Ronaghi sold 10,000 shares of Illumina stock. The stock was sold at an average price of $347.07, for a total value of $3,470,700.00.

Shares of NASDAQ:ILMN opened at $319.51 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.46 and a quick ratio of 2.24. The stock has a market cap of $45.63 billion, a P/E ratio of 79.88, a price-to-earnings-growth ratio of 2.30 and a beta of 1.07. Illumina, Inc. has a 12-month low of $205.41 and a 12-month high of $372.61.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.26. The firm had revenue of $853.00 million during the quarter, compared to the consensus estimate of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The company’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the company earned $1.11 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 5.75 EPS for the current year.

A number of analysts have issued reports on ILMN shares. UBS Group started coverage on Illumina in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $340.00 target price for the company. BidaskClub downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Cowen raised their price objective on Illumina from $315.00 to $400.00 and gave the stock a “positive” rating in a research report on Thursday, September 6th. ValuEngine downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Finally, Piper Jaffray Companies raised their price objective on Illumina to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 2nd. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $330.94.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Kaizen Advisory LLC grew its position in Illumina by 161.0% in the 2nd quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock valued at $103,000 after acquiring an additional 227 shares in the last quarter. Moneta Group Investment Advisors LLC grew its position in Illumina by 2,670.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after acquiring an additional 9,345 shares in the last quarter. Sun Life Financial INC grew its position in Illumina by 152.5% in the 2nd quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after acquiring an additional 241 shares in the last quarter. Highstreet Asset Management Inc. acquired a new position in Illumina in the 3rd quarter valued at about $112,000. Finally, Migdal Insurance & Financial Holdings Ltd. grew its position in Illumina by 3,192.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock valued at $120,000 after acquiring an additional 415 shares in the last quarter. 90.13% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Illumina, Inc. (ILMN) SVP Sells 10,000 Shares of Stock” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2018/11/16/insider-selling-illumina-inc-ilmn-svp-sells-10000-shares-of-stock.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.